Operating lease liabilities, net of current portion
122
159
196
148
Total liabilities
7,084
9,671
6,988
10,819
Series a convertible preferred stock, 0.0001 par value, 5,000 shares authorized 965 issued and outstanding at march31, 2026 and december31, 2025 liquidation preference of 5,000 at march31, 2026 and december31, 2025
-
4,940
4,940
4,940
Common stock, 0.0001 par value, 125000000 and 40,000 shares authorized 25,400 and 10,767 shares issued and outstanding at june30, 2026 and december31, 2025, respectively
3
1
1
1
Additional paid-in capital
95,481
83,093
58,536
56,987
Accumulated other comprehensive loss
0
-8
-14
-4
Accumulated deficit
-76,754
-70,398
-63,500
-60,164
Total serina therapeutics, inc. stockholders (deficit) equity
-
-
-37
1,760
Noncontrolling deficit
-
-
0
-166
Total stockholders' equity (deficit)
18,730
17,628
-37
1,594
Total liabilities and stockholders equity (deficit)
25,814
27,299
6,951
12,413
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.